Login / Signup

Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.

Sean R O'NeilGarrett A WeberDustin A DemingMark E BurkardParaic A KennyCraig S RichmondBenjamin M Parsons
Published in: JCO precision oncology (2023)
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • dna damage
  • cell death
  • advanced non small cell lung cancer
  • reactive oxygen species
  • metastatic renal cell carcinoma
  • wild type
  • breast cancer risk
  • young adults